国产热热热精品,亚洲视频久久】日韩,三级婷婷在线久久,99人妻精品视频,精品九热人人肉肉在线,AV东京热一区二区,91po在线视频观看,久久激情宗合,青青草黄色手机视频

   

Anti-graft campaign hits drug watchdog

(China Daily)
Updated: 2007-02-05 07:01

The recent corruption scandals swirling around the pharmaceutical industry have led to speculation that more people are involved and the national food-and-drug watchdog might have its wings clipped.

All State Food and Drug Administration (SFDA) officials, incumbent and retired, have been asked to prove their innocence, reported China Business newspaper yesterday.

Those who abused power for personal gain were asked to hand in illicitly-obtained money or assets by last Friday or face harsher punishment, an SFDA insider told the newspaper.

Related readings:
Stricter checks on medicines
Stricter quality checks on 170,000 medicines
Former drug head faces graft probe
Blood drug recalled for 'violations'
China punishes manufactuer of suspect killer antibiotic
New medicare system relieves burden of rural residents
Medical reforms trim health costs
Right to equal medical care
Minister pledges healthcare for all
Medical service network builded
Blue book: Medical costs China's top social concern
The SFDA has been under a cloud ever since a series of corrupt officials were uncovered last year. It culminated with December's announcement that Zheng Xiaoyu, former chief of the SFDA, was under investigation by the Central Commission for Discipline Inspection, the Party's anti-graft watchdog.

Zheng has been accused of taking huge bribes and abusing his power to grant favors to his relatives during his 8-year-rein in the SFDA since 1998.

Earlier, several of his former subordinates, including two of his secretaries, were netted for bribe taking.

A series of anti-graft warnings and correctional efforts presided over by new SFDA chief Shao Mingli suggest an overhaul is imminent.

The scandal has also toppled some entrepreneurs reportedly implicated with the Zheng case, with the latest being Tang Xudong, president of Hangzhou-based Kangliyuan Group. The pharmaceutical company has been ordered to suspend operation.

Meanwhile, "the State Council is considering taking away the power to supervise food and health care products from the SFDA and establishing an exclusive committee under the State Council in charge of food safety," the insider was quoted as saying.

The right to approve new drugs might also be taken from the SFDA and given to another committee under the State Council, he said.

"The SFDA's power will then be greatly reduced and there will be no need for its existence as a vice-ministerial level department," he said. "It might be merged with another ministry."

In 2002, China adopted a national standard under which medicines have to be approved by the SFDA before sale. The change, which granted great power to the SFDA, bred rampant corruption to secure drug approvals.



Top China News  
Today's Top News  
Most Commented/Read Stories in 48 Hours
新泰市| 雅安市| 类乌齐县| 伊金霍洛旗| 玉树县| 香河县| 绥棱县| 拜泉县| 黑山县| 丰镇市| 巩留县| 垫江县| 永安市| 敖汉旗| 平安县| 乐昌市| 铜山县| 阿克陶县| 革吉县| 博爱县| 伊金霍洛旗| 葵青区| 清新县| 海安县| 贵德县| 阳新县| 二手房| 旺苍县| 临江市| 改则县| 武义县| 铜川市| 连云港市| 称多县| 临安市| 仁布县| 建瓯市| 达孜县| 诸暨市| 清新县| 新闻|